C1-esterase Inhibitor Treatment is Associated with Immune and Vascular Pathway Modulation in PASC with Neurological Symptoms: Longitudinal Plasma Proteomics
Open Access
- 19 May 2026
- journal article
- Published by Springer Nature in Cellular and Molecular Neurobiology
- Vol. 46 (1)
Abstract
Post-acute sequelae of SARS-CoV-2 infection (PASC), particularly neurological manifestations, remain a significant therapeutic challenge, likely driven by persistent inflammation, immune dysregulation, and endothelial dysfunction. In a randomized, double-blind, placebo-controlled crossover trial, 10 patients with post-COVID-19 neurological symptoms received C1-esterase inhibitor (C1-INH; RUCONEST®) or placebo over two eight-week phases. Longitudinal plasma proteomics (SomaScan®) profiled molecular dynamics during and after C1-INH treatment. C1-INH administration was associated with distinct, phase-specific proteomic signatures, including lower levels of inflammatory-associated proteins such as CRP and IL-6, increased levels of neuroimmune and endothelial repair proteins (Neuropilin-2, CD83, C1QTNF5), and modulation of bradykinin-kinin and extracellular matrix pathways. These molecular shifts were evaluated in relation to clinical change scores during the active treatment windows. Several proteomic changes were observed at timepoint 26 after treatment cessation, describing candidate post-treatment molecular trajectories. In conclusion, these results provide exploratory mechanistic insights and support the need for validation in larger, prospective cohorts. Together, these findings prioritize immune and vascular pathways for further investigation in PASC and may have relevance to other post-infectious neuroimmune conditions.Keywords
Funding Information
- Pharming Healthcare Inc.
This publication has 45 references indexed in Scilit:
- A modular map of Bradykinin-mediated inflammatory signaling networkJournal of Cell Communication and Signaling, 2021
- The Neurological Manifestations of Post-Acute Sequelae of SARS-CoV-2 InfectionCurrent Neurology and Neuroscience Reports, 2021
- C1 Esterase Inhibition: Targeting Multiple Systems in COVID-19Journal of Clinical Immunology, 2021
- Bradykinin receptor‐1 activation induces inflammation and increases the permeability of human brain microvascular endothelial cellsCell Biology International, 2019
- Knockdown of circulating C1 inhibitor induces neurovascular impairment, glial cell activation, neuroinflammation, and behavioral deficitsGlia, 2019
- Update on the Use of C1-Esterase Inhibitor Replacement Therapy in the Acute and Prophylactic Treatment of Hereditary AngioedemaClinical Reviews in Allergy & Immunology, 2018
- Sustained response of recombinant human C1 esterase inhibitor for acute treatment of hereditary angioedema attacksAnnals of Allergy, Asthma & Immunology, 2017
- Association of IL-12p70 and IL-6:IL-10 ratio with autism-related behaviors in 22q11.2 deletion syndrome: A preliminary reportBrain, Behavior, and Immunity, 2013
- TRAIL suppresses tumor growth in mice by inducing tumor-infiltrating CD4+CD25+ Treg apoptosisCancer Immunology, Immunotherapy, 2012
- The bradykinin-forming cascade and its role in hereditary angioedemaAnnals of Allergy, Asthma & Immunology, 2010